‘INITIATING ADVANCED STAGE CLINICAL TRIALS FOR NEW DRUG’

“As indicated in our slogan, GBC is thriving to develop breakthrough medicine patients desire. Patients always want to have their medical conditions treated with less adverse effects. However, modern medicines always come with undesired side effects and drug resistance. With its multi-target property, HOCENA from GBC shall be a much better choice than the mono-therapies and combination therapies in terms of efficacy and safety respectively in treating complex diseases such as COVID-19, NASH, and Alzheimer’s disease. GBC’s major goals for 2022 are to initiate advanced stage clinical trials for these diseases (phase III for COVID-19, phase II for both NASH & Alzheimer’s disease) and to ensure the quality and quantity of HOCENA supply in an affordable and accessible fashion.”

- ALEX LIU, Chairman, Golden Biotechnology Corp. (GBC), Taiwan